tbuckley/cabot-search huggingface dataset:
Secondary depression: familial, clinical, and research perspectives
Authors: N C Andreasen, G Winokur
Journal: American Journal of Psychiatry (1979)

The authors evaluate the clinical and research significance of the diagnosis of secondary depression by comparing 48 cases of primary and 26 cases of secondary depression. The patients with secondary depression have a higher familial prevalence of alcoholism, affective disorder, and drug abuse. The groups differ somewhat on a few sociodemographic, behavioral, and attitudinal variables but are similar in symptomatology, sex ratio, onset and duration of symptoms, treatment received, and response to treatment. These results suggest that the distinction between primary and secondary depression should be retained in research that examines neurochemistry or genetics. Primary and secondary depression appear to be identical from the persepctive of clinical care. Management of these patients should emphasize the diagnosis of depression rather than antecedent diagnoses.
Abstract A53: Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment.
Authors: AJ Robert McGray, Cheryl Eppolito, Kyle Stephenson, Jonathan Pol, Brian Lichty, Kunle Odunsi
Journal: Clinical Cancer Research (2016)

Abstract While spectacular responses have been observed in some patients following cancer immunotherapy, the majority of responses are short-lived with ultimate tumor relapse. Therefore, it is crucial to identify strategies that will effectively synergize with immunotherapies to improve clinical outcome. Oncolytic viruses (OV) are replication-competent viruses that can infect and kill tumor cells, while also acting as potent immune adjuvants. Additionally, as OV can be engineered to express tumor antigens, we are investigating the use of OV as vaccine vectors with the capacity to enhance immune responses to defined tumor antigen targets. Based on these unique attributes of OV, we hypothesized that OV could be effectively combined with multiple immunotherapeutic strategies currently in clinical testing as a means of enhancing anti-tumor immunity and improving tumor growth control/treatment outcome. Targeting a model tumor antigen in a pre-clinical ovarian cancer model, we observed that delivery of oncolytic Maraba virus (MRB) following vaccination enhanced tumor-specific CD8+ T cell expansion and trafficking to the tumor microenvironment, reduced intratumoral Tregs and MDSC frequencies, and resulted in improved survival compared to vaccination alone. Additionally, when MRB was combined with adoptive T cell transfer (ACT) of tumor-specific CD8+ T cells, this combination resulted in improved persistence of the transferred T cells and enhanced tumor control compared to treatment with MRB or ACT alone. Lastly, a dramatic improvement in treatment efficacy was observed when MRB was combined with checkpoint blockade (anti-PD-L1) compared to either monotherapy. These data suggest that OV can effectively synergize with multiple cancer immunotherapies currently being explored. Our current studies are focused on combining OV with either vaccines or ACT strategies that target clinically relevant ovarian cancer antigens (WT1, Sp17, and NY-ESO-1) using syngeneic and humanized mouse models. Additionally, we are exploring the transcriptional profile of tumors treated with immunotherapy + OV to identify gene signatures that correlate with improved therapeutic efficacy. Citation Format: AJ Robert McGray, Cheryl Eppolito, Kyle Stephenson, Jonathan Pol, Brian Lichty, Kunle Odunsi. Combining oncolytic virotherapy with immunotherapy for ovarian cancer treatment. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A53.
Elevated growth hormone responses to pyridostigmine in obsessive- compulsive disorder: evidence of cholinergic supersensitivity
Authors: J V Lucey, G Butcher, A W Clare, T G Dinan
Journal: American Journal of Psychiatry (1993)

The growth hormone response to the acetylcholinesterase inhibitor pyridostigmine was measured in nine normothymic outpatients who met DSM-III-R criteria for obsessive-compulsive disorder. The responses were significantly elevated when compared to those found in a healthy comparison group (N = 9). The data suggest that cholinergic supersensitivity is present in obsessive-compulsive disorder.
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration
Authors: Chan Y. Cheah, Paul J. Bröckelmann, Dai Chihara, Alison J. Moskowitz, Andreas Engert, Mats Jerkeman, Tarec C. El‐Galaly, Bradley Augustson, Julie Vose, Nancy L. Bartlett, Diego Villa, Joseph M. Connors, Tatyana Feldman, Chelsea C. Pinnix, Sarah A. Milgrom, Bouthaina Dabaja, Yasuhiro Oki, Michelle A. Fanale
Journal: American Journal of Hematology (2016)

Central nervous system (CNS) involvement is rare in patients with Hodgkin lymphoma (HL). Thus, the clinical features and outcomes are not well described. Cases of histologically confirmed CNS HL diagnosed between 1995 and 2015 were retrospectively identified in institutional (n = 7), national (n = 2), and cooperative group (n = 1) databases. We screened 30,781 patients with HL in our combined databases and identified 21 patients meeting eligibility criteria, an estimated frequency of 0.07%. CNS involvement was present at initial diagnosis in 10 patients (48%) and a feature of relapsed/refractory disease in 11 (52%). Among these 11 patients, the median time from initial diagnosis of HL to development of CNS involvement was 1.9 years (range 0.4-6.6) and the median number of prior lines of therapy was 2 (range 1-7). Altogether, treatments included radiation, multiagent systemic chemotherapy, combined modality therapy, and subtotal resection. The overall response rate was 65%. After a median follow-up of 3.6 years (range 0.8-13.2) from diagnosis of CNS HL, the median PFS and OS were 7.6 and 29 months, respectively. CNS involvement as a feature of relapsed/refractory disease was adversely prognostic for both PFS and OS; however, four patients remain alive and free of relapse at 7-78 months follow-up. CNS involvement in HL is exceedingly rare and has a distinct clinical presentation with predilection for parenchymal lesions with dural extension. Around one-quarter of patients, mostly with CNS involvement at initial HL diagnosis, experience prolonged disease-free survival. Am. J. Hematol. 91:894-899, 2016. © 2016 Wiley Periodicals, Inc.
Are anorexic and bulimic patients depressed?
Authors: D B Herzog
Journal: American Journal of Psychiatry (1984)

The presence of depression was assessed in 82 female outpatients with anorexia nervosa and bulimia by means of a structured interview. The Research Diagnostic Criteria for major depressive disorder were met by 55.6% of the anorexic patients and 23.6% of the bulimic patients. On the Extracted Hamilton Depression Rating Scale, 40.7% of the patients with anorexia and 23.6% of those with bulimia had scores in the moderately or severely depressed range.
Depression associated with nifedipine-induced calcium channel blockade
Authors: F J Hullett, S G Potkin, A B Levy, R Ciasca
Journal: American Journal of Psychiatry (1988)

Four cases are reported in which substantial depression was associated with the use of the calcium channel blocker nifedipine. In one instance, a patient became unresponsive to treatment with nortriptyline when nifedipine was introduced. In each case, the depression resolved following discontinuation of nifedipine. Possible mechanisms by which nifedipine may influence affective states are discussed.
Prevention of Preterm Delivery
Authors: Ellen A B Morrison, Linda F Cushman
Journal: New England Journal of Medicine (2007)

To the Editor: The review article on prevention of preterm delivery, by Simhan and Caritis (Aug. 2 issue),1 may suggest that oxytocin-receptor antagonists should not be used for the treatment of preterm labor because of a possible excess of fetal and infant deaths. We believe that the authors rely on studies that are methodologically questionable, based on the literature. The elevated infant mortality in the studies cited is probably related to randomization bias, in our view.2,3 More recent randomized trials4,5 show similar tocolytic efficacy, fewer maternal side effects, and no excess infant deaths with atosiban, as compared with other tocolytic agents, and atosiban is therefore used in many European countries.
Extroversion and neuroticism in young men at higher or lower risk for alcoholism
Authors: M A Schuckit
Journal: American Journal of Psychiatry (1983)

The Eysenck Personality Inventory extroversion and neuroticism scores of 32 nonalcoholic young men with an alcoholic close relative and of controls were not significantly different. This implies that these personality attributes are not related to a predisposition to alcoholism.
A prospective randomized controlled trial of ATP-based tumor chemosensitivity assay (ATP-TCA) directed chemotherapy <i>versus</i> physician’s choice in patients with recurrent platinum-resistant ovarian cancer
Authors: I. A. Cree, C. M. Kurbacher, A. Lamont, A. C. Hindley
Journal: Journal of Clinical Oncology (2005)

5008 Background: Ovarian cancers show considerable heterogeneity in their response to chemotherapy. We sought to establish whether an ATP-based tumour chemosensitivity assay (ATP-TCA) could aid the choice of chemotherapy and improve outcome, based on encouraging results from a previous case control study (Kurbacher et al., Anti-Cancer Drugs 1998; 9: 51–7). Methods: The primary aim of this randomized open label trial was to determine response rate and progression free survival (PFS) following chemotherapy in patients with platinum-resistant recurrent ovarian cancer treated according to the ATP-TCA, or by physician’s choice. All patients showing evidence of progression within 6 months of cessation of primary platinum-based therapy were eligible, if they were fit for further chemotherapy. The study was designed to accrue 180 patient equally between the two arms to detect a 20% difference in outcome with 80% power and 99% confidence. Results: A total of 180 patients were randomised to assay-directed (n = 94) or physician’s choice chemotherapy (n = 86). In each case, tumor or ascitic fluid was sent from the treating centres (n = 10) for assay to one of two central laboratories (UK or Germany). Median follow-up at analysis was 18 months. Treatment choice was balanced between the groups, with increased use of combination therapy in the physician’s choice arm during the study. Response was assessable in 147 patients with 31.5% of patients achieving a partial/complete response in the physician’s choice group, compared with 40.5% in the assay-directed group. ITT analysis showed a median progression-free survival (PFS) of 93 days in the physician’s choice group and 104 days in the assay-directed group (Logrank p < 0.14). There was no difference in overall survival between the groups, and none of the differences observed achieved statistical significance. Conclusions: This study shows a trend towards improved response and PFS for assay-directed treatment with high response rates in both arms, probably due to the balanced use of combination therapy designed using the ATP-TCA in this poor prognosis group of patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration CanTech Ltd., LANCE CanTech Ltd., LANCE
Abstract P1-09-02: Higher incidence of second cancers in African American (AA) patients compared to Caucasian patients with a primary breast cancer
Authors: N Diab, G Clark, B Hamlington, L Brzeskiewicz, L Langer, S Diab
Journal: Cancer Research (2016)

Abstract Background: AA women with breast cancer have lower survival rates compared to Caucasian women. Since this lower survival rate may be related to genetic mutations, and environmental/socioeconomically factors, we hypothesize that the same factors may lead to a higher risk of secondary cancers after an initial diagnosis of breast cancer. Method: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Program data using Multiple Primary - Standardized Incidence Ratio parameters. The incidence of second cancer diagnoses in AA and Caucasian women previously diagnosed with breast was compared to the incidence of cancer in the general population matched by age, race, and year of diagnosis. Results are reported as the observed risk divided by the expected risk (O/E). Results: For the 43,688 AA pts, the overall O/E and excess risks were 1.48 and 51.2 compared to 1.11 and 14.7 for the 428,103 Caucasian patients. The mean ages of diagnoses of initial breast cancer diagnosis and second cancer were 57.2 and 65 years for AA patients compared to 61.8 and 70.2 years for Caucasian patients. The following is a summary of statically significant (p &amp;lt;0.05) selected O/E by the site of second cancer : O/E for AA and white by site of second cancerSiteAAWhiteOral Cavity and Pharynx1.651.41Digestive System1.181Respiratory System1.271.13Skin excluding Basal and Squamous1.931.33Breast1.671.18Female Genital System1.110.95Urinary System1.561.18Endocrine System1.521.38All Lymphatic and Hematopoietic Diseases1.261.05 This higher risk of second cancers occurred despite the lower relative survival rate for AA compared to Caucasian patients with a 5-year relative survival rate of 68.6% for AA and 78.3% for Caucasian patients. Conclusions: To our knowledge, this is the first report of the incidence of second cancers in AA patients with breast cancer compared to caucasian. More research to understand the biological, genetic, therapeutic, and environmental factors leading to this higher risk of second cancers is warranted. Citation Format: Diab N, Clark G, Hamlington B, Brzeskiewicz L, Langer L, Diab S. Higher incidence of second cancers in African American (AA) patients compared to Caucasian patients with a primary breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-09-02.
Response to Letters Regarding Article, “Infective Endocarditis After Transcatheter Aortic Valve Implantation: Results From a Large Multicenter Registry”
Authors: Ignacio J. Amat-Santos, David Messika-Zeitoun, Helene Eltchaninoff, Samir Kapadia, Stamatios Lerakis, Asim N. Cheema, Enrique Gutiérrez-Ibanes, Antonio Munoz, Manuel Pan, John G. Webb, Howard Herrmann, Susheel Kodali, Luis Nombela-Franco, Corado Tamburino, Hasan Jilaihawi, Jean-Bernard Masson, Fabio Sandoli de Brito, Maria Cristina Ferreira, Valter Correa Lima, José Armando Mangione, Bernard Iung, Alec Vahanian, Eric Durand, Murat Tuzcu, Salim S. Hayek, Rocio Angulo-Llanos, Juan J. Gómez-Doblas, Juan Carlos Castillo, Danny Dvir, Martin B. Leon, Eulogio Garcia, Javier Cobiella, Marco Barbanti, Raj Makkar, Henrique Barbosa Ribeiro, Marina Urena, Eric Dumont, Philippe Pibarot, Javier Lopez, Alberto San Roman, Josep Rodés-Cabau
Journal: Circulation (2015)
Asbestos Exposure and Serum Osteopontin
Authors: Akio Hiraki, Keisuke Aoe, Hiroshi Ueoka
Journal: New England Journal of Medicine (2006)

To the Editor: Pass et al. (Oct. 13 issue)1 report that elevated osteopontin levels in workers with pleural disease who have been exposed to asbestos support a diagnosis of mesothelioma. The authors acknowledge that other cancers express osteopontin, and they mention the need for further studies. The expression of osteopontin in numerous benign inflammatory and fibrotic lung diseases,2 which considerably limits the potential use of osteopontin as a tumor marker, was not discussed. In addition to the osteopontin levels associated with lung carcinoma, similar levels are seen in tuberculosis, interstitial lung diseases, and cardiac disease.2,3 These clinical entities pose diagnostic difficulties in patients with asbestosrelated pleural disease. Therefore, measurement of osteopontin levels is unlikely to help diagnostically in this clinical scenario. The functional diversity of osteopontin in part reflects allelic variation and extensive post-translational modification.2 Certain isoforms of osteopontin have differing biologic functions.4 Tumorderived osteopontin functions in a manner distinct from non–tumor-derived osteopontin.5 Much as specific isoforms may account for the role of osteopontin in cancer, future studies may define variants with higher diagnostic potential. Until then, the specificity of osteopontin measurement is too low for it to be used as a screening tool for mesothelioma. Anthony W. O’Regan, M.D. National University of Ireland, Galway Galway, Ireland anthony.oregan@whb.ie
Non-virally engineered human adipose mesenchymal stem cells produce BMP4, target brain tumors, and extend survival
Authors: Antonella Mangraviti, Stephany Y. Tzeng, David Gullotti, Kristen L. Kozielski, Jennifer E. Kim, Michael Seng, Sara Abbadi, Paula Schiapparelli, Rachel Sarabia-Estrada, Angelo Vescovi, Henry Brem, Alessandro Olivi, Betty Tyler, Jordan J. Green, Alfredo Quinones-Hinojosa
Journal: Biomaterials (2016)
E rosette negative T cell acute lymphocytic leukemia.
Authors: A Bernard
Journal: Journal of Clinical Oncology (1986)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1986.4.8.1281 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3488375 E rosette negative T cell acute lymphocytic leukemia. A BernardxA BernardSearch for articles by this author https://doi.org/10.1200/JCO.1986.4.8.1281 PDF "E rosette negative T cell acute lymphocytic leukemia.." Journal of Clinical Oncology, 4(8), pp. 1281–1282© 1986 by American Society of Clinical Oncology
Associations between quantitative computed tomography (qCT) measures of emphysema and mortality
Authors: Ane Johannessen, Trude Duelien Skorge, Thomas Blix Grydeland, Harvey Coxson, Ernst Omenaas, Amund Gulsvik, Per Bakke
Journal: European Respiratory Journal (2011)

Background:  Knowledge is limited regarding associations between qCT measures of emphysema and mortality.   Aims:  To examine 6-year mortality (all-cause and chronic lower airway diseases (ICD-10 codes J40-J47)) in relation to qCT measures of emphysema.   Methods:  In the Norwegian GenKOLS study 2003-05, 947 ever-smokers (49% with COPD) aged 40-85 years performed spirometry and qCT examination. Lung inflation level was obtained by dividing CT measured lung volume by predicted TLC. CT emphysema was estimated using% of lung voxels with X-ray attenuation values less than -950 Hounsfield units (% low-attenuation areas (LAA)), expressed in population quintiles. Mortality data from 2003-09 were gathered from the Norwegian Cause of Death Registry. Gender-stratified Cox proportional hazards were modelled, adjusting for FEV1, COPD status, age, BMI, smoking, inflation level.   Results:  Both all-cause (n=106) and chronic lower airway diseases mortality (n=31) increased with%LAA: from 3% and 0.5% in the lowest quintile to 32% and 12% in the highest quintile. Unadjusted hazard ratios (HR) (95% CI) for all-cause mortality were 14.1 (6.2, 32.0) for the highest quintile for women, and 8.4 (4.4, 16.1) for men. After adjustment, the trends remained the same, but were (borderline) significant only for women (HR 3.7 (95% CI 0.9, 14.3). For chronic lower airway mortality, the highest quintile%LAA had HR (95%CI) 47.2 (6, 377) for women, and 39.7 (5, 301) for men. After adjustment, upper%LAA quintile had HR 17.6 (95%CI 1, 308) for women and 2.5 (0, 47) for men.   Conclusions:  qCT measures of emphysema are related to mortality, especially in women. Subjects with high%LAA have a substantially elevated mortality risk.
Antidepressant effects of right versus left unilateral ECT and the lateralization theory of ECT action
Authors: R Abrams, C M Swartz, C Vedak
Journal: American Journal of Psychiatry (1989)

In a random-assignment, double-blind, controlled comparison of right versus left unilateral ECT in 30 melancholic men, the two methods were not significantly different in overall antidepressant potency, although there was a significantly faster rate of improvement with left unilateral ECT. These results imply that the antidepressant effects of ECT cannot be attributed primarily to right hemisphere mechanisms, as others have postulated.
Mapping the future dynamics of disease transmission: risk analysis in the United Kingdom Foresight Programme on the detection and identification of infectious diseases
Authors: J E Suk, C Lyall, J Tait
Journal: Eurosurveillance (2008)

This paper reflects on the qualitative risk analysis framework developed for a Foresight study on the Detection and Identification of Infectious Diseases, which was coordinated in 2005 by the United Kingdom (UK) under what is now the Government Office for Science, Department for Innovation, Universities and Skills. The risk assessment covered human, plant and animal diseases in the UK and Africa in the years 2015 and 2030. Through engaging a diverse pool of experts, we developed a model conceptualising disease spread as the outcome of interactions among sources, pathways and drivers. We then used this model to conduct a Delphi survey of experts. The factors perceived most likely to contribute to infectious disease spread in 2015 and 2030 included geographic extension of existing pathogens (partially due to climate change), over-use of antibiotics/antivirals/pesticides leading to drug resistance, and zoonoses. Our methodology provides a framework for those who need to integrate a wide range of perspectives and factors into their planning and analyses.